‘Transformative Event’ For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi

First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications. The update follows First Wave BioPharma’s disappointing topline results from its Phase 2 SPAN trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for exocrine pancreatic insufficiency in cystic fibrosis patients. Though initial data indicated that enhanced adrulipase formulation was safe and well tolerated, it was likely …

Read More